LEVBIO: 29% sales growth and improved results, but future revenue to decline after CyberGene sale
· Issued by Level Bio AB
Net sales grew 29% to 32.4 MSEK in 2025, with improved profitability and strong performance from Techtum Lab. The divestment of CyberGene post-year-end strengthens the balance sheet but will reduce future sales and margins.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
